When do antidepressants worsen the course of bipolar disorder?

Journal of Psychiatric Practice

Volumn 9, Issue 3, 2003, Pages 181-194

  Goldberg, Joseph F ^a  

^a ZUCKER HILLSIDE HOSPITAL   (United States)

Author keywords

Anticonvulsants; Antidepressants; Antipsychotics; Bipolar depression; Bipolar disorder; Bupropion; Divalproex; Hypomania; Lamotrigine; Lithium; Mania; Mood stabilizers; Olanzapine; Rapid cycling; Selective serotonin reuptake inhibitors (SSRIs)

Indexed keywords

AMFEBUTAMONE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; CARBAMAZEPINE; CITALOPRAM; DESIPRAMINE; FLUOXETINE; IMIPRAMINE; LAMOTRIGINE; LITHIUM; MIRTAZAPINE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRANYLCYPROMINE; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROATE SEMISODIUM; VENLAFAXINE;

ARTICLE; BIPOLAR DEPRESSION; BIPOLAR DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE EXACERBATION; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; HUMAN; HYPOMANIA; MANIA; MOOD; MOOD DISORDER QUESTIONNAIRE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; SUICIDAL BEHAVIOR;

EID: 0038650537     PISSN: 15274160     EISSN: None     Source Type: Journal    
DOI: 10.1097/00131746-200305000-00002     Document Type: Article

References (127)

1. Ghaemi SN, Boiman EE, Goodwin FK. Diagnosing bipolar disorder and the effect of antidepressants: A naturalistic study. J Clin Psychiatry 2000;61:804-8.
2. Hantouche EG, Akiskal HS, Lancrenon S, et al. Systematic clinical methodology for validating bipolar-II disorder: Data in mid-stream from a French national multi-site study (EPIDEP). J Affect Disord 1998;50:163-73.
3. Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse: Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 1990;264:2511-8.
4. Kessler RC, MeGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: Results from the National Comorbidity Survey. Arch Gen Psychiatry 1994;51:8-19.
5. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. Washington, DC: American Psychiatric Association; 1994.
6. Akiskal HS, Bourgeois ML, Angst J, et al. Re-evaluating the prevalence of and diagnostic composition within the broad clinical spectrum of bipolar disorders. J Affect Disord 2000;59(Suppl 1): S5-S30.
7. Hirschfeld RM, Calabrese JR, Weissman MM. Screening for bipolar disorder in the community. J Clin Psychiatry 2003;64:53-9.
8. Angst F, Stassen HH. Suicide risk in patients with major depressive disorder. J Clin Psychiatry 1999;60(Suppl 2): 57-62.
9. Blacker D, Tsuang MT. Contested boundaries of bipolar disorder and the limits of categorical diagnosis in psychiatry. Am J Psychiatry 1992;149:1473-83.
10. Perugi G, Micheli C, Akiskal HS, et al. Polarity of the first episode, clinical characteristics, and course of manic depressive illness: A systematic retrospective investigation of 320 bipolar I patients. Compr Psychiatry 2000;41:13-8.
11. Ernst CL, Goldberg JF. Antidepressant properties of anticonvulsant drugs for bipolar disorder. J Clin Psychopharmacol 2003;23:182-92.
12. Ghaemi SN, Sachs GS, Chiou AM, et al. Is bipolar disorder still underdiagnosed? Are antidepressants overutilized? J Affect Disord 1999;52:135-44.
13. Bowden CL. Strategies to reduce misdiagnosis of bipolar depression. Psychiatr Serv 2001;52:51-5.
14. Akiskal HS. The prevalent clinical spectrum of bipolar disorders: Beyond DSM-IV. J Clin Psychopharmacol 1996;16: 4S-14S.
15. Akiskal J. The emerging epidemiology of hypomania and bipolar II disorder. J Affect Disord 1998;50:143-51.
16. Maj M, Pirozzi R, Formicola AM, et al. Reliability and validity of four alternative definitions of rapid cycling bipolar disorder. Am J Psychiatry 1999;156:1421-4.
17. Lish JD, Dime-Meenan S, Whybrow PC, et al. The National Depressive and Manic-Depressive Association (DMDA) survey of bipolar members. J Affect Disord 1994;31:281-94.
18. Hirschfeld RM, Lewis L, Vornik LA. Perceptions and impact of bipolar disorder: How far have we really come? Results of the National Depressive and Manic-Depressive Association 2000 survey of individuals with bipolar disorder. J Clin Psychiatry 2003;64:161-74.
19. Goldberg JF, Ernst CL. Features associated with the delayed initiation of mood stabilizers at illness onset in bipolar disorder. J Clin Psychiatry 2002;63:985-91.
20. McElroy SL, Altshuler LL, Suppes T, et al. Axis I psychiatric comorbidity and its relationship to historical illness variables in 288 patients with bipolar disorder. Am J Psychiatry 2001;158:420-6.
21. Geller B, Zimerman B, Williams M, et al. Bipolar disorder at prospective follow-up of adults who had prepubertal major depressive disorder. Am J Psychiatry 2001;158:125-7.
22. Goldberg JF, Harrow M, Whiteside JE. Risk for bipolar illness in patients initially hospitalized for unipolar depression. Am J Psychiatry 2001;158:1265-70.
23. Goldberg JF, Truman T. Antidepressant-induced mania: An overview of current controversies. Bipolar Disord, in press.
24. Delbello MP, Soutullo CA, Hendricks W. Prior stimulant treatment in adolescents with bipolar disorder: Association with age at onset. Bipolar Disord 2001;3:53-7.
25. Nemeroff CB, Evans DL, Gyulai L, et al. Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression. Am J Psychiatry 2001;158: 906-12.
26. Young LT, Joffe RT, Robb JC, et al. Double-blind comparison of addition of a second mood stabilizer versus an antidepressant to an initial mood stabilizer for treatment of patients with bipolar depression. Am J Psychiatry 2000;157:124-6.
27. Ghaemi SN, Lenox MS, Baldessarini RJ. Effectiveness and safety of long-term antidepressant treatment in bipolar disorder. J Clin Psychiatry 2001;62:565-9.
28. Goodwin FK, Jamison KR. Manic-depressive illness. New York: Oxford University Press; 1990.
29. Sachs GS, Printz DJ, Kahn DA, et al. The expert consensus guidelines series: Medication treatment of bipolar disorder 2000. Postgrad Med Special Report 2000 (April): 1-104.
30. Practice guideline for the treatment of patients with bipolar disorder (Revision). Am J Psychiatry 2002;159:1-50.
31. IMS America. National disease and therapeutic index. Fairfield, CT: IMS Health; 1998.
32. Frances A, Docherty JP, Kahn DA. The expert consensus guidelines series: Treatment of bipolar disorder. J Clin Psychiatry 1996;57(suppl 12A):1-88.
33. Peet M. Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants. Br J Psychiatry 1994;164:549-50.
34. Post RM, Altshuler LL, Frye MA, et al. Rate of switch in bipolar patients prospectively treated with second-generation antidepressants as augmentation to mood stabilizers. Bipolar Disord 2001;3:259-65.
35. Goldberg JF, Whiteside JE. The association between substance abuse and antidepressant-induced mania in bipolar disorder: A preliminary study. J Clin Psychiatry 2002;63: 791-5.
36. Mundo E, Walker M, Cate T, et al. The role of serotonin transporter protein gene in antidepressant-induced mania in bipolar disorder: Preliminary findings. Arch Gen Psychiatry 2001; 58:539-44.
37. Truman C, Baldassano C, Goldberg JF, et al. History of anti-depressant-induced mania in the STEP-500. New Research Poster to be presented at the 156th Annual Meeting of the American Psychiatric Association, San Francisco, CA, May 17-22, 2003.
38. Cohn JB, Collins G, Ashbrook E, et al. A comparison of fluoxetine, imipramine and placebo in patients with bipolar depressive disorder. Int Clin Psychopharmacol 1989;4: 313-22.
39. Himmelhoch JM, Thase ME, Mallinger AG, et al. Tranylcypromine versus imipramine in anergic bipolar depression. Am J Psychiatry 1991;148:910-6.
40. Thase ME, Mallinger AG, McKnight D, et al. Treatment of imipramine-resistant recurrent depression, IV: A double-blind crossover study of tranylcypromine for anergic bipolar depression. Am J Psychiatry 1992;149:195-8.
41. Sachs GS, Lafer B, Stoll AL, et al. A double-blind trial of bupropion versus desipramine for bipolar depression. J Clin Psychiatry 1994;55:391-3.
42. Silverstone T. Moclobemide vs. imipramine in bipolar depression: A multicentre double-blind clinical trial. Acta Psychiatr Scand 2001;104:104-9.
43. Tohen M; Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine/fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry, in press.
44. Vieta E, Martinez-Aran A, Goikolea JM, et al. A randomized trial comparing paroxetine and venlafaxine in the treatment of bipolar depressed patients taking mood stabilizers. J Clin Psychiatry 2002;63:508-12.
45. Sachs GS. Design and promise of NIMH multicenter effectiveness trials: A STEP forward. Presented at 4th International Congress on Bipolar Disorder. Pittsburgh, PA: June 14-16, 2001.
46. Amsterdam J. Efficacy and safety of venlafaxine in the treatment of bipolar II major depressive episode. J Clin Psychopharmacol 1998;18:414-7.
47. Amsterdam JD, Garcia-Espana F. Venlafaxine monotherapy in women with bipolar II and unipolar major depression. J Affect Disord 2000;59:225-9.
48. Altshuler L, Kiriakos L, Calcagno J, et al. The impact of anti-depressant discontinuation versus antidepressant continuation on 1-year risk for relapse of bipolar depression: A retrospective chart review. J Clin Psychiatry 2001;62:612-6.
49. Angst J. Switch from depression to mania: A record study over decades between 1920 and 1982. Psychopathology 1985;18: 140-54.
50. Kupfer DJ, Carpenter LL, Frank E. Possible role of antide-pressants in precipitating mania and hypomania in recurrent depression. Am J Psychiatry 1988;145:804-8.
51. Wehr TA, Goodwin FK. Can antidepressants cause mania and worsen the course of affective illness? Am J Psychiatry 1987;144:1403-11.
52. Altshuler LL, Post RM, Leverich GS, et al. Antidepressant-induced mania and cycle acceleration: A controversy revisited. Am J Psychiatry 1995;152:1130-8.
53. Ko JY, Ghaemi SN, Kontos NJ, et al. Antidepressant wear off and outcomes in bipolar versus unipolar depression. Presented at 155th Annual Meeting of the American Psychiatric Association. Washington, DC: American Psychiatric Association 2002 Annual Meeting; May 18-23, 2002 (Abstracts on Disk).
54. Stoll AL, Mayer PV, Kolbrener M, et al. Antidepressant-associated mania: A controlled comparison with spontaneous mania. Am J Psychiatry 1994;151:1642-5.
55. Howland RH. Induction of mania with serotonin reuptake inhibitors. J Clin Psychopharmacol 1996;16:425-7.
56. Gupta N. Venlafaxine-induced hypomanic switch in bipolar depression. Can J Psychiatry 2001;46:760-1.
57. Fogelson DL, Bystritsky A, Pasnau R. Bupropion in the treatment of bipolar disorders: The same old story? J Clin Psychiatry 1992;53:443-6.
58. Bauer MS, Calabrese J, Dunner DL, et al. Multisite data reanalysis of the validity of rapid cycling as a course modifier for bipolar disorder in DSM-IV. Am J Psychiatry 1994;151: 506-15.
59. Prien RF, Kupfer DJ, Mansky PA, et al. Drug therapy in the prevention of recurrences in unipolar and bipolar affective disorders: Report of the NIMH Collaborative Study Group comparing lithium carbonate, imipramine, and a lithium carbonate-imipramine combination. Arch Gen Psychiatry 1984;41:1096-1104.
60. Wehr TA, Sack DA, Rosenthal NE, et al. Rapid cycling affective disorder: Contributing factors and treatment responses in 51 patients. Am J Psychiatry 1988;145:179-84.
61. Henry C, Sorbara F, Lacoste J, et al. Antidepressant-induced mania in bipolar patients: Identification of risk factors. J Clin Psychiatry 2001;62:249-55.
62. Bottlender R, Rudolf D, Straub A, et al. Mood-stabilisers reduce the risk of developing antidepressant-induced maniform states in acute treatment of bipolar I depressed patients. J Affect Disord 2001;63:79-84.
63. Van Putten T, May RP. "Akinetic depression" in schizophrenia. Arch Gen Psychiatry 1978;35:1101-7.
64. Goldberg JF. Spontaneous depression versus biphasic cycling and the treatment of bipolar depression (letter). Am J Psychiatry 2001;158:325-6.
65. MacQueen GM, Young LT, Marriott MJ. Dr. MacQueen and colleagues reply. Am J Psychiatry 2001;158:326.
66. Gabbay V, O'Dowd MA, Asnis GM. Combined antidepressant treatment: A risk factor for switching in bipolar patients (letter). J Clin Psychiatry 2002;63:367.
67. Henry C. Reply to Drs. Gabbay, O'Dowd and Asnis (letter). J Clin Psychiatry 2002;63:367-8.
68. Goldstein TR, Frye MA, Denicoff KD, et al. Antidepressant discontinuation-related mania: Critical prospective observation and theoretical implications in bipolar disorder. J Clin Psychiatry 1999;60:563-7.
69. Li X, Bijur GN, Jope RS. Glycogen synthase kinase-3beta, mood stabilizers, and neuroprotection. Bipolar Disord 2002;4: 137-44.
70. Michael-Titus AT, Bains S, Jeetle J, et al. Imipramine and phenelzine decrease glutamate overflow in the prefrontal cortex: A possible mechanism of neuroprotection in major depression? Neuroscience 2000;100:681-4.
71. Ketter TA, Post RM, Theodore WH. Positive and negative psychiatric effects of antiepileptic drugs in patients with seizure disorders. Neurology. 1999;53:S53-S67.
72. Judd LL, Akiskal HS, Schettler PJ, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 2002;59:530-7.
73. Angst F, Stassen HH, Clayton PJ, et al. Mortality of patients with mood disorders: Follow-up over 34-38 years. J Affect Disord 2002;68:167-81.
74. Moller HJ, Grunze H. Have some guidelines for the treatment of acute bipolar depression gone too far in the restriction of antidepressants? Eur Arch Psychiatry Clin Neurosci 2000;250:57-68.
75. Leon AC, Keller MB, Warshaw MG, et al. Prospective study of fluoxetine treatment and suicidal behavior in affectively ill subjects. Am J Psychiatry 1999;156:195-201.
76. Goldberg JF, Michaelis B, Endick CJ, et al. Differential pharmacotherapy and suicidal ideation in the STEP-500 bipolar cohort. Poster presented at the 41st Annual Meeting of the American College of Neuropsychopharmacology, San Juan, Puerto Rico, December 8-13, 2002.
77. Goldberg JF, Garno JL, Portera L, et al. Correlates of suicidal ideation in dysphoric mania. J Affect Disord 1999;56:75-81.
78. Bauer MS, Callahan AM, Jampala C, et al. Clinical practice guidelines for bipolar disorder from the Department of Veterans Affairs. J Clin Psychiatry 1999;60:9-21.
79. Tondo L, Baldessarini RJ. Reduced suicide risk during lithium maintenance treatment. J Clin Psychiatry 2000;61(Suppl 9):97-104.
80. Greil W, Kleindienst N, Erazo N, et al. Differential response to lithium and carbamazepine in the prophylaxis of bipolar disorder. J Clin Psychopharmacol 1998;18:455-60,
81. Ahrens B, Muller-Oerlinghausen B. Does lithium exert an independent antisuicidal effect? Pharmacopsychiatry 2001;34:132-6.
82. Meltzer HY, Alphs L, Green AI, et al. International Suicide Prevention Trial Study Group: Clozapine treatment for suicidality in schizophrenia. International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry 2003;60:82-91.
83. Bowden CL, Calabrese JR, Wallin BA, et al. Illness characteristics of patients in clinical drug studies of mania. Psychopharmacol Bull 1995;3:103-9.
84. Amsterdam JD, Garcia-Espana F, Fawcett J, et al. Efficacy and safety of fluoxetine in treating bipolar II major depressive episode. J Clin Psychopharmacol 1998;18:435-40.
85. Dunner DL, Tay LK. Diagnostic reliability of the history of hypomania in bipolar II patients and patients with major depression. Compr Psychiatry 1993;34:303-7.
86. Akiskal HS, Walker P, Puzantian VR, et al. Bipolar outcome in the course of depressive illness: Phenomenologic, familial, and pharmacologic predictors. J Affect Disord 1983;5:115-28.
87. Coryell W, Endicott J, Maser JD, et al. Long-term stability of polarity distinctions in the affective disorders. Am J Psychiatry 1995;152:385-90.
88. Kovacs M. Presentation and course of major depressive disorder during childhood and later years of the life span. J Am Acad Child Adolesc Psychiatry 1996;35:705-15.
89. Mitchell PB, Wilhelm K, Parker G, et al. The clinical features of bipolar depression: A comparison with matched major depressive disorder patients. J Clin Psychiatry 2001;62: 212-6.
90. Benazzi F. Sensitivity and specificity of clinical markers for the diagnosis of bipolar II disorder. Compr Psychiatry 2001;42:461-5.
91. Winokur G, Coryell W, Endicott J, et al. Further distinctions between manic-depressive illness (bipolar disorder) and primary depressive disorder (unipolar depression). Am J Psychiatry 1993;150:1176-81.
92. Strober M, Carlson G. Bipolar illness in adolescents with major depression: Clinical, genetic, and psychopharmacologic predictors in a three- to four-year prospective follow-up investigation. Arch Gen Psychiatry 1982;39:549-55.
93. Cassano GB, Akiskal HS, Musetti L, et al. Psychopathology, temperament, and past course in primary major depressions. 2. Toward a redefinition of bipolarity with a new semistructured interview for depression. Psychopathology 1989;22: 278-88.
94. Akiskal HS, Maser JD, Zeller PJ, et al. Switching from 'unipolar' to bipolar II: An 11-year prospective study of clinical and temperamental predictors in 559 patients. Arch Gen Psychiatry 1995;52:114-23.
95. Perugi G, Akiskal HS, Lattanzi L, et al. The high prevalence of "soft" bipolar (II) features in atypical depression. Compr Psychiatry 1998;39:63-71.
96. Dunner DL. Bipolar disorders in DSM-IV: Impact of inclusion of rapid cycling as a course modifier. Neuropsychopharmacology 1998;19:189-93.
97. Maj M. Diagnosis and treatment of rapidly cycling bipolar disorder. Eur Arch Psychiatry Clin Neurosci 2001;251(Suppl 2):II62-II65.
98. Hirschfeld RM, Williams JB, Spitzer RL, et al. Development and validation of a screening instrument for bipolar spectrum disorder: The Mood Disorder Questionnaire. Am J Psychiatry 2000;157:1873-5.
99. Hirschfeld RM, Holzer C, Calabrese JR, et al. Validity of the mood disorder questionnaire. Am J Psychiatry 2003;160: 178-80.
100. Strakowski SM, McElroy SL, Keck PE. Clinical efficacy of valproate in bipolar illness: Comparisons and contrasts with lithium. In: Halbreich U, Montgomery SA, eds. Pharmacotherapy for mood, anxiety, and cognitive disorders. Washington, DC: American Psychiatric Press; 2000:143-57.
101. Zornberg GL, Pope HG Jr. Treatment of depression in bipolar disorder: New directions for research. J Clin Psychopharmacol 1993;13:397-408.
102. Prien RF, Caffey EM Jr, Klett CJ. Prophylactic efficacy of lithium carbonate in manic-depressive illness: Report of the Veterans Administration and National Institute of Mental Health collaborative study group. Arch Gen Psychiatry 1973;28:337-41.
103. Dunner DL, Stallone F, Fieve RR. Lithium carbonate and affective disorders. V: A double-blind study of prophylaxis of depression in bipolar illness. Arch Gen Psychiatry 1976;33:117-20.
104. Bowden CL, Calabrese JR, McElroy SL, et al. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. Arch Gen Psychiatry 2000;57: 481-9.
105. Bowden CL, Calabrese JR, Sachs GS, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry 2003;60: 392-400.
106. Bowden CL, Ghaemi SN, Gyulai L, et al. Lamotrigine delays mood episodes in recently depressed bipolar I patients (605 data). Presented at 155th Annual Meeting of the American Psychiatric Association. Washington, DC: American Psychiatric Association Annual Meeting; May 18-23, 2002 (Abstracts on Disk).
107. Sachs G, Altshuler L, Ketter T, et al. Divalproex versus placebo for the treatment of bipolar depression. Presented at 40th Annual Meeting of the American College of Neuropsychopharmacology; Waikoloa, HI: Dec 9-13, 2001.
108. Lambert PA, Venaud G. Comparative study of valpromide versus lithium in the treatment of bipolar disorder. Nervure 1992;5:57-65.
109. Calabrese JR, Bowden CL, Sachs GS, et al. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. J Clin Psychiatry 1999;60:79-88.
110. Calabrese JR, Rapport DJ, Kimmel SE, et al. Controlled trials in bipolar I depression: Focus on switch rates and efficacy. Eur Neuropsychopharmacol 1999;9(suppl 4):S109-S112.
111. Calabrese JR, Suppes T, Bowden CL, et al. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapidcycling bipolar disorder. Lamictal 614 Study Group. J Clin Psychiatry 2000;61:841-50.
112. Walden J, Hesslinger B, van Calker D, et al. Addition of lamotrigine to valproate may enhance efficacy in the treatment of bipolar affective disorder. Pharmacopsychiatry 1996;29:193-5.
113. Sporn J, Sachs G. The anticonvulsant lamotrigine in treatment-resistant manic-depressive illness. J Clin Psychopharmacol 1997;17:185-9.
114. Chengappa KN, Gershon S, Levine J. The evolving role of topiramate among other mood stabilizers in the management of bipolar disorder. Bipolar Disord 2001;3:215-32.
115. McIntyre RS, Mancini DA, McCann S, et al. Topiramate versus bupropion SR when added to mood stabilizer therapy for the depressive phase of bipolar disorder: A preliminary single-blind study. Bipolar Disord 2002;4:207-13.
116. Pande AC, Crockatt JG, Janney CA, et al. Gabapentin in bipolar disorder: A placebo-controlled trial of adjunctive therapy. Gabapentin Bipolar Disorder Study Group. Bipolar Disord 2000;2:249-55.
117. Frye MA, Ketter TA, Kimbrell TA, et al. A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J Clin Psychopharmacol 2000;20:607-14.
118. Pande AC, Davidson JR, Jefferson JW, et al. Treatment of social phobia with gabapentin: A placebo-controlled study. J Clin Psychopharmacol 1999;19:341-8.
119. Pande AC, Pollack MH, Crockatt J, et al. Placebo-controlled study of gabapentin treatment of panic disorder. J Clin Psychopharmacol 2000;20:467-71.
120. Serpell MG. Neuropathic pain study group. Gabapentin in neuropathic pain syndromes: A randomised, double-blind, placebo-controlled trial. Pain 2002;99:557-66.
121. Rose MA, Kam PC. Gabapentin: Pharmacology and its use in pain management. Anaesthesia 2002;57:451-62.
122. Sanger TM, Grundy SL, Gibson PJ, et al. Long-term olanzapine therapy in the treatment of bipolar I disorder: An openlabel continuation phase study. J Clin Psychiatry 2001;62: 273-81.
123. Vieta E, Reinares M, Corbella B, et al. Olanzapine as longterm adjunctive therapy in treatment-resistant bipolar disorder. J Clin Psychopharmacol 2001;21:469-73.
124. Tohen M, Ketter TA, Zarate CA Jr., et al. Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance remission: A 47-week study. Am J Psychiatry, in press.
125. Tohen M, Marneros W, Greil W. Olanzapine versus lithium relapse prevention in bipolar disorder: A randomized double-blind controlled 12-month trial. Presented at the Third European Stanley Foundation Conference on Bipolar Disorder, September 12-14, 2002, Freiburg, Germany.
126. Stahl S, Shelton RC. Risperidone, paroxetine or the combination in bipolar depression. Presented at the 40th Annual Meeting of the American College of Neuropsychopharmacology, December 9-13, 2001, Waikoloa, HI.
127. Ketter TA, Calabrese JR. Stabilization of mood from below versus above baseline in bipolar disorder: A new nomenclature. J Clin Psychiatry 2002;63:146-51.